139 related articles for article (PubMed ID: 12492812)
1. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes.
Zhang Y; Stroobant V; Russo V; Boon T; van der Bruggen P
Tissue Antigens; 2002 Nov; 60(5):365-71. PubMed ID: 12492812
[TBL] [Abstract][Full Text] [Related]
2. Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
Corbière V; Nicolay H; Russo V; Stroobant V; Brichard V; Boon T; van der Bruggen P
Tissue Antigens; 2004 May; 63(5):453-7. PubMed ID: 15104676
[TBL] [Abstract][Full Text] [Related]
3. New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells.
Kobayashi T; Lonchay C; Colau D; Demotte N; Boon T; van der Bruggen P
Tissue Antigens; 2003 Nov; 62(5):426-32. PubMed ID: 14617050
[TBL] [Abstract][Full Text] [Related]
4. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
[TBL] [Abstract][Full Text] [Related]
5. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44.
Godelaine D; Carrasco J; Brasseur F; Neyns B; Thielemans K; Boon T; Van Pel A
Cancer Immunol Immunother; 2007 Jun; 56(6):753-9. PubMed ID: 17096150
[TBL] [Abstract][Full Text] [Related]
6. A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.
Vantomme V; Boël P; De Plaen E; Boon T; van der Bruggen P
Cancer Immun; 2003 Dec; 3():17. PubMed ID: 14664500
[TBL] [Abstract][Full Text] [Related]
7. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells.
Ottaviani S; Zhang Y; Boon T; van der Bruggen P
Cancer Immunol Immunother; 2005 Dec; 54(12):1214-20. PubMed ID: 16025263
[TBL] [Abstract][Full Text] [Related]
8. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
9. A new MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A24 carcinoma cells.
Ottaviani S; Colau D; van der Bruggen P; van der Bruggen P
Cancer Immunol Immunother; 2006 Jul; 55(7):867-72. PubMed ID: 16151806
[TBL] [Abstract][Full Text] [Related]
10. A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes.
Luiten R; van der Bruggen P
Tissue Antigens; 2000 Feb; 55(2):149-52. PubMed ID: 10746786
[TBL] [Abstract][Full Text] [Related]
11. Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses.
Breckpot K; Heirman C; De Greef C; van der Bruggen P; Thielemans K
J Immunol; 2004 Feb; 172(4):2232-7. PubMed ID: 14764691
[TBL] [Abstract][Full Text] [Related]
12. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
Schultz ES; Lethé B; Cambiaso CL; Van Snick J; Chaux P; Corthals J; Heirman C; Thielemans K; Boon T; van der Bruggen P
Cancer Res; 2000 Nov; 60(22):6272-5. PubMed ID: 11103782
[TBL] [Abstract][Full Text] [Related]
13. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome.
Schultz ES; Chapiro J; Lurquin C; Claverol S; Burlet-Schiltz O; Warnier G; Russo V; Morel S; Lévy F; Boon T; Van den Eynde BJ; van der Bruggen P
J Exp Med; 2002 Feb; 195(4):391-9. PubMed ID: 11854353
[TBL] [Abstract][Full Text] [Related]
14. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes.
Schultz ES; Zhang Y; Knowles R; Tine J; Traversari C; Boon T; van der Bruggen P
Tissue Antigens; 2001 Feb; 57(2):103-9. PubMed ID: 11260504
[TBL] [Abstract][Full Text] [Related]
15. A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.
Bilsborough J; Panichelli C; Duffour MT; Warnier G; Lurquin C; Schultz ES; Thielemans K; Corthals J; Boon T; van der Bruggen P
Tissue Antigens; 2002 Jul; 60(1):16-24. PubMed ID: 12366779
[TBL] [Abstract][Full Text] [Related]
16. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma.
Huang LQ; Brasseur F; Serrano A; De Plaen E; van der Bruggen P; Boon T; Van Pel A
J Immunol; 1999 Jun; 162(11):6849-54. PubMed ID: 10352307
[TBL] [Abstract][Full Text] [Related]
17. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein.
Zhang Y; Chaux P; Stroobant V; Eggermont AM; Corthals J; Maillère B; Thielemans K; Marchand M; Boon T; Van Der Bruggen P
J Immunol; 2003 Jul; 171(1):219-25. PubMed ID: 12817001
[TBL] [Abstract][Full Text] [Related]
18. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
van der Bruggen P; Bastin J; Gajewski T; Coulie PG; Boël P; De Smet C; Traversari C; Townsend A; Boon T
Eur J Immunol; 1994 Dec; 24(12):3038-43. PubMed ID: 7805731
[TBL] [Abstract][Full Text] [Related]
19. Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.
So T; Hanagiri T; Chapiro J; Colau D; Brasseur F; Yasumoto K; Boon T; Coulie PG
Cancer Immunol Immunother; 2007 Feb; 56(2):259-69. PubMed ID: 16758204
[TBL] [Abstract][Full Text] [Related]
20. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
